Black Diamond Therapeutics Inc

Black Diamond Therapeutics maintains a strong liquidity position, with a current ratio of 8.42 and $20.99 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage risk. The liquidity FPT (free cash flow to total liabilities) is 0.736, further reinforcing the company's strong liquidity profile. The company's profitability is notable, with a net income of $22.37 million and an operating income of $12.52 million, translating to a return on equity (ROE) of 19.93% and a return on assets (ROA) of 15.64%. These metrics exceed the typical performance of the biotechnology industry, where ROE and ROA are often lower due to high R&D costs and long development cycles. Black Diamond Therapeutics does not disclose segment or geographic revenue breakdowns in the latest financial data, making it difficult to assess revenue concentration or geographic exposure. However, the company's operations are primarily based in the United States, and its pipeline is focused on global therapeutic markets, suggesting a broad geographic reach. The company's growth trajectory is positive, with a revenue of $70 million and a net income of $22.37 million in the latest period. Analysts have set a mean price target of $9.86, with a median of $10.00, indicating strong confidence in the company's future performance. The mean recommendation of 1.78 (on a scale from 1 to 5) further supports a positive outlook. The risk assessment for Black Diamond Therapeutics is favorable, with low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is free of long-term debt. The dilution potential is low, and no significant dilution sources were identified in the latest filings. Recent events and filings indicate a stable and growing company. The company has a strong cash position and is generating positive free cash flow, which supports its ongoing R&D activities and potential future growth. Analysts have provided a range of price targets from $7.00 to $14.00, with a strong buy recommendation from three analysts and a buy recommendation from five analysts.